ClinicalTrials.gov
ClinicalTrials.gov Menu

Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02343042
Recruitment Status : Recruiting
First Posted : January 21, 2015
Last Update Posted : April 9, 2018
Sponsor:
Information provided by (Responsible Party):
Karyopharm Therapeutics Inc

Brief Summary:

This study will independently assess the efficacy and safety of six combination therapies for the treatment of patients with Relapsed/Refractory Multiple Myeloma (RR MM) and Newly Diagnosed Multiple Myeloma (NDMM). The combinations to be evaluated include: selinexor + pomalidomide + dexamethasone (SPd), selinexor + bortezomib + dexamethasone (SVd), selinexor + lenalidomide + dexamethasone (SRd), selinexor + pomalidomide + dexamethasone + bortezomib (SPVd), selinexor + daratumumab + dexamethasone (SDd), and selinexor + carfilzomib + dexamethasone (SKd).

The abbreviations for combination treatments have been revised to use V (Velcade) for bortezomib, R (Revlimid) for lenalidomide, D (Darzalex) for daratumumab, and K (Kyprolis) for carfilzomib.


Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Selinexor Drug: Dexamethasone Drug: Lenalidomide Drug: Pomalidomide Drug: Bortezomib Drug: Daratumumab Drug: Carfilzomib Phase 1 Phase 2

Detailed Description:

Multi-center, open-label, randomized (for dose schedule) clinical study with dose escalation (Phase 1) and expansion (Phase 2) stages to independently assess the maximum tolerated dose (MTD,) efficacy, and safety of selinexor + pomalidomide + dexamethasone (SPd), selinexor + bortezomib + dexamethasone (SVd), selinexor + lenalidomide + dexamethasone (SRd), selinexor + pomalidomide + dexamethasone + bortezomib (SPVd), selinexor + daratumumab + dexamethasone (SDd), and selinexor + carfilzomib + dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (RR MM) and newly diagnosed multiple myeloma (ND MM).

SPVd arm will not open for enrollment until further notice.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 321 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma
Actual Study Start Date : October 2015
Estimated Primary Completion Date : March 2019
Estimated Study Completion Date : April 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1: Selinexor, Low-dose Dexamethasone & Pomalidomide (SPd)

Pomalidomide will be dosed at 4 mg daily for 21 days per cycle.

Cohort 1.1: Selinexor 80 mg with dexamethasone 40 mg once weekly.

Cohort 1.2: Selinexor 60 mg with dexamethasone 20 mg twice weekly; dexamethasone 40 mg weekly will also be given (without selinexor) on Days 22 & 24.

Drug: Selinexor
Tablets
Other Name: KPT-330
Drug: Dexamethasone
Oral tablets in a multi-dose vial.
Other Name: Decadron
Drug: Pomalidomide
4 mg oral tablets
Other Name: Pomalyst
Experimental: 2: Selinexor, Low-dose Dexamethasone & Bortezomib (SVd)

One cycle is either 21 or 35 days (depending on bortezomib dosing schedule).

Cohort 2.1: Selinexor 80 mg with dexamethasone 40 mg once weekly. Bortezomib 1.3 mg/m2 subcutaneous (SC) once weekly.

Cohort 2.2: Selinexor 60 mg with dexamethasone 20 mg twice weekly; dexamethasone 40 mg weekly will also be given on Days 29 and 31. Bortezomib 1.3 mg/m2 SC dosed once weekly.

Drug: Selinexor
Tablets
Other Name: KPT-330
Drug: Dexamethasone
Oral tablets in a multi-dose vial.
Other Name: Decadron
Drug: Bortezomib
3.5 mg for injection supplied as lyophilized powder in single-use viles for subcutaneous injection.
Other Name: Velcade
Experimental: 3: Selinexor, Low-dose dexamethasone, & Lenalidomide (SRd)

Lenalidomide at 25mg daily for 21 days per 28 day cycle.

Cohort 3.1: Selinexor 80mg with dexamethasone 40mg once weekly.

Cohort 3.2: Selinexor 60mg with dexamethasone 20mg twice weekly; dexamethasone 40mg weekly will also be given (without selinexor) on Days 22 and 24.

Drug: Selinexor
Tablets
Other Name: KPT-330
Drug: Dexamethasone
Oral tablets in a multi-dose vial.
Other Name: Decadron
Drug: Lenalidomide
25 mg Oral capsule
Other Name: REVLIMID
Experimental: 4:Selinexor,Low-dose dexamethasone,Pomalidomide,Velcade (SPVd)

Cohort 4.1: Selinexor 100 mg with dexamethasone 40 mg once weekly. Pomalidomide at 4 mg daily for 21 days per 28 day cycle. Bortezomib 1.3 mg/m2 subcutaneous (SC) once weekly.

Cohort 4.2: Selinexor 60 mg with dexamethasone 20 mg twice weekly. Pomalidomide at 4 mg daily for 21 days per 28 day cycle. Bortezomib 1.3 mg/m2 subcutaneous (SC) once weekly.

Note: This arm is not open for enrollment at any institution in this study.

Drug: Selinexor
Tablets
Other Name: KPT-330
Drug: Dexamethasone
Oral tablets in a multi-dose vial.
Other Name: Decadron
Drug: Pomalidomide
4 mg oral tablets
Other Name: Pomalyst
Drug: Bortezomib
3.5 mg for injection supplied as lyophilized powder in single-use viles for subcutaneous injection.
Other Name: Velcade
Experimental: 5: Selinexor, Low-dose dexamethasone, & Daratumumab (SDd)

Daratumumab at 16 mg/kg IV every week for cycles 1 and 2; then every 2 weeks for cycles 3-6, then once a month for cycles 6 and beyond.

Cohort 5.1: Selinexor 100 mg once weekly, with dexamethasone or equivalent dose of other corticosteroid, given intravenously or by mouth, 40 mg weekly in single or divided doses.

Cohort 5.2: Selinexor 60 mg twice weekly with dexamethasone or equivalent dose of other corticosteroid, given intravenously or by mouth, 40 mg weekly in single or divided doses.

Drug: Selinexor
Tablets
Other Name: KPT-330
Drug: Dexamethasone
Oral tablets in a multi-dose vial.
Other Name: Decadron
Drug: Daratumumab
16 mg/kg Intravenous
Other Name: Darzalex
Experimental: 6: Selinexor, Low-dose Dexamethasone, & Carfilzomib (Skd)
Cohort 6.1: Selinexor 100 mg with dexamethasone 40 mg once weekly. Carfilzomib 56 mg/m2 IV once weekly per 28 day cycle.
Drug: Selinexor
Tablets
Other Name: KPT-330
Drug: Dexamethasone
Oral tablets in a multi-dose vial.
Other Name: Decadron
Drug: Carfilzomib
56 mg/m2 Intravenous
Other Name: Kyprolis
Experimental: 7: Selinexor,Low-dose Dexamethasone,Lenalidomide (SRd) NDMM
Cohort 7.1 in Newly Diagnosed MM: Selinexor 60 mg with dexamethasone 40 mg once weekly. Lenalidomide at 25 mg daily for 21 days per 28 day cycle.
Drug: Selinexor
Tablets
Other Name: KPT-330
Drug: Dexamethasone
Oral tablets in a multi-dose vial.
Other Name: Decadron
Drug: Lenalidomide
25 mg Oral capsule
Other Name: REVLIMID



Primary Outcome Measures :
  1. Maximal Tolerated Dose (MTD) and Recommended Phase 2 dose (RP2D) for Selinexor [ Time Frame: 12 months ]
    - Determine the MTD and RP2D; selinexor once weekly or twice weekly for all arms.


Secondary Outcome Measures :
  1. Number of patients with Adverse Events as a measure of safety and tolerability [ Time Frame: 12 months ]
    - Evaluate the safety and tolerability of selinexor + pomalidomide + dexamethasone (SPd), selinexor + bortezomib + dexamethasone (SVd), selinexor + lenalidomide + dexamethasone (SRd), selinexor + pomalidomide + dexamethasone + bortezomib (SPVd), selinexor + daratumumab + dexamethasone (SDd), and selinexor + carfilzomib + dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma and selinexor + lenalidomide + dexamethasone (SRd) in patients with newly diagnosed multiple myeloma, using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), v 4.03.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written informed consent in accordance with federal, local, and institutional guidelines.
  2. Age ≥ 18 years at the time of informed consent
  3. Histologically confirmed diagnosis, measurable disease and evidence of disease progression of MM, as described below.
  4. Symptomatic MM, based on IMWG guidelines. Patients must have measurable disease as defined by at least one of the following:

    1. Serum M-protein ≥ 0.5 g/dL by serum protein electrophoresis (SPEP) or, for IgA myeloma, by quantitative IgA
    2. Urinary M-protein excretion at least 200 mg/24 hours
    3. Serum FLC ≥ 100 mg/L, provided that FLC ratio is abnormal
    4. If serum protein electrophoresis is felt to be unreliable for routine M-protein measurement (e.g., for IgA MM), then quantitative Ig levels by nephelometry or turbidometry are acceptable.
  5. Any non-hematological toxicities (except for peripheral neuropathy as described in exclusion criterion #24) that patients experienced from treatments in previous clinical studies must have resolved to ≤ Grade 2 by Cycle 1 Day 1.
  6. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2.
  7. Adequate hepatic function within 21 days prior to C1 D1:

    • For SPd and SRd: Total bilirubin < 2x ULN (except patients with Gilbert's syndrome [hereditary indirect hyperbilirubinemia] who must have a total bilirubin of ≤ 3x ULN) and both AST and ALT < 2.5x ULN)
    • For SVd, SPVd and SDd): Total bilirubin of ≤ 1.5x ULN (except patients with Gilbert's syndrome [hereditary indirect hyperbilirubinemia] who must have a total bilirubin of ≤ 3x ULN) and both AST and ALT < 2.0x ULN)
  8. Adequate renal function within 21 days prior to C1 D1:

    • Estimated creatinine clearance of (calculated using the formula of Cockroft and Gault):
    • ≥ 20 mL/min for SVd, SPVd, and SDd Arms
    • ≥ 45 mL/min for SPd Arm (as requested by the manufacturer)
    • > 50 mL/min for SRd Arm
  9. Adequate hematopoietic function within 21 days prior to C1 D1: total white blood cell (WBC) count ≥ 1,500/mm3, ANC ≥ 1000/mm3, hemoglobin (Hb) ≥ 8.0 g/dL, and platelet count ≥ 75,000/mm3. For expansion cohorts only, platelet counts > 50,000/mm3; for patients in whom ≥ 50% of bone marrow nucleated cells are plasma cells, platelets or ≥ 30,000/mm3 are acceptable for expansion cohorts. Patients receiving hematopoietic growth factor support, including erythropoietin (EPO), darbepoetin, granulocyte-colony stimulating factor (G-CSF), granulocyte macrophagecolony stimulating factor (GM-CSF), and platelet stimulators (e.g., eltrombopag or romiplostim) may continue to do so. However, patients in the escalation cohorts must be platelet transfusion independent for > 1 week in order to be enrolled in the study.
  10. Female patients of child-bearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at Screening. Male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential. Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal. For both male and female patients, effective methods of contraception must be used throughout the study and for three months following the last dose.

    SPd (Arm 1) Only:

  11. Relapsed and refractory MM with:

    1. Documented evidence of PD after achieving at least SD for ≥ 1 cycle during a previous MM regimen (i.e., relapsed MM)
    2. ≤ 25% response (i.e., patients never achieved ≥ MR) or PD during or within 60 days from the end of the most recent MM regimen (i.e., refractory MM)
    3. Previously undergone ≥ 2 cycles of lenalidomide and a proteasome inhibitor (in separate therapeutic regimens [not for maintenance] or in combination)
    4. In the expansion arm at RP2D, patients must not be pomalidomide refractory

    SVd (Arm 2) Only:

  12. Relapsed or refractory MM with

    1. Documented evidence of relapse after ≥ 1 previous line of therapy
    2. Not refractory to bortezomib in their most recent line of therapy

    SRd in RRMM (Arm 3) Only:

  13. Patients who received ≥ 1 prior therapeutic regimen (prior lenalidomide is allowed as long as patient's MM was not refractory to prior lenalidomide; patients whose MM was refractory to lenalidomide maintenance regimens will be allowed in this cohort).

    SPVd (Arm 4) Only:

  14. Patients whose MM is relapsing after ≥ 1 prior therapy with progression on their last therapy.

    SDd (Arm 5) Only:

  15. Patients who received ≥ 3 prior lines of therapy, including a PI and an IMiD, or patients with MM refractory to both a PI and an IMiD.
  16. Patients must not have received prior daratumumab therapy (Cohort 5.3 ONLY - dose expansion at RP2D).

    SKd (Arm 6) Only:

  17. Patients may have received prior bortezomib or carfilzomib therapy, however their MM must NOT be refractory to carfilzomib.

    SRd in NDMM (Arm 7) Only:

  18. Patients must have symptomatic myeloma per IMWG guidelines with either CRAB criteria or Myeloma Defining Events and need systemic therapy.
  19. No prior systemic therapy for NDMM is permitted other than pulse dose dexamethasone (maximum dose of 160 mg).

Exclusion Criteria:

Patients meeting any of the following exclusion criteria are not eligible to enroll in this study:

  1. Smoldering MM
  2. MM that does not express M-protein or FLC (i.e., non-secretory MM is excluded), and quantitative immunoglobulin levels cannot be used instead
  3. Documented active systemic amyloid light chain amyloidosis
  4. Active plasma cell leukemia
  5. Blood (or blood product) transfusions and blood growth factors within 7 days of C1D1 (only for patients enrolling into the Expansion Phase)
  6. Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤ 2 weeks prior to C1D1, and radio-immunotherapy within 6 weeks prior to C1D1. Patients on long-term glucocorticoids during Screening do not require a washout period. Prior radiation is permitted for treatment of fractures or to prevent fractures as well as for pain management
  7. Patients with history of SCC with residual paraplegia (Dose Escalation Phase only).
  8. Treatment with an investigational anti-cancer therapy within 3 weeks prior to C1D1
  9. Prior autologous stem cell transplantation < 1 month, or allogeneic stem cell transplantation < 3 months prior to C1D1
  10. Active graft versus host disease after allogeneic stem cell transplantation
  11. Life expectancy < 3 months
  12. Major surgery within 4 weeks prior to C1D1
  13. Active, unstable cardiovascular function:

    1. Symptomatic ischemia, or
    2. Uncontrolled clinically-significant conduction abnormalities (e.g., patients with ventricular tachycardia on antiarrhythmics are excluded; patients with 1st degree atrioventricular (AV) block or asymptomatic left anterior fascicular block/right bundle branch block (LAFB/RBBB) will not be excluded), or
    3. Congestive heart failure (CHF) of New York Heart Association (NYHA) Class ≥ 3, or
    4. Myocardial infarction (MI) within 3 months prior to C1D1
    5. Ejection fraction (EF) < 50% at Screening
  14. Uncontrolled active hypertension
  15. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose
  16. Known active hepatitis A, B or C
  17. Known HIV infection or HIV seropositivity
  18. Any active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of study treatment
  19. Currently pregnant or breastfeeding
  20. A serious psychiatric or medical condition which, in the opinion of the Investigator, could interfere with treatment
  21. Hypersensitivity to any of the treatments for the Arm in which the patient is enrolled
  22. In the SVd (Arm 2) only: Prior history of neuropathy Grade > 2, or Grade 2 neuropathy with pain at screening (within 21 days prior to C1D1)
  23. Prior exposure to a SINE compound, including selinexor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02343042


Contacts
Contact: Michael Kauffman, MD, PhD mkauffman@karyopharm.com
Contact: Sharon Shacham, PhD SShacham@karyopharm.com

Locations
United States, California
Jonnsson Comprehensive Cancer Center / University of Los Angeles Recruiting
Los Angeles, California, United States, 0095
Contact: Gary Schiller, MD, PhD    888-798-0719    GSchiller@mednet.ucla.edu   
Principal Investigator: Gary Schiller, MD, PhD         
United States, New York
Columbia University Recruiting
New York, New York, United States, 10032
Contact: Suzanne Lentzsch, MD    212-305-5065    CTOInformation@columbia.edu   
Principal Investigator: Suzanne Lentzsch, MD         
Wilmot Cancer Center/ University of Rochester Recruiting
Rochester, New York, United States
Contact: Brea Lipe, MD       Brea_Lipe@URMC.Rochester.edu   
Principal Investigator: Brea Lipe, MD         
United States, North Carolina
Duke Institute of Cancer/ Duke University Recruiting
Durham, North Carolina, United States, 27710
Contact: Cristina Gasparetto, MD    919-668-1017    gaspa001@mc.duke.edu   
Principal Investigator: Cristina Gasparetto, MD         
United States, Washington
Swedish Cancer Institute Recruiting
Seattle, Washington, United States, 98109
Contact: William Bensinger, MD    855-922-6237      
Principal Investigator: William Bensinger, MD         
Canada, Alberta
Tom Baker Cancer Center/Alberta Health Services Recruiting
Calgary, Alberta, Canada, T2N 4Z6
Contact: Nizar Bahlis, MD    +1 (403) 944-1880    nbahlis@ucalgary.ca   
Principal Investigator: Nizar Bahlis, MD         
Cross Cancer Institute / University of Alberta Recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Contact: Chris Venner    780-432-8771      
Principal Investigator: Chris Venner, MD         
Canada, British Columbia
Vancouver General Hospital Recruiting
Vancouver,, British Columbia, Canada, V5Z 1M9
Contact: Heather Sutherland    604.736.2033      
Principal Investigator: Heather Sutherland, MD         
Canada, Manitoba
Cancer Care Manitoba Active, not recruiting
Winnipeg, Manitoba, Canada, R3E 0V9
Canada, Newfoundland and Labrador
Memorial Hospital of Newfoundland Active, not recruiting
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
Canada, Nova Scotia
Queen Elizabeth II Health Sciences Center Recruiting
Halifax, Nova Scotia, Canada, B3H 2Y9
Contact: Darrell White         
Principal Investigator: Darrell White, MD         
Canada, Ontario
Princess Margaret Cancer Centre Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Saima Dean    416 946 4501 ext 5241      
Principal Investigator: Christine Chen         
Canada, Quebec
Maisonneuve-Rosemont Hospital Active, not recruiting
Montreal, Quebec, Canada, H1T 2M4
Royal Victoria Hospital / McGill University Active, not recruiting
Montreal, Quebec, Canada, H3A 1A1
Sponsors and Collaborators
Karyopharm Therapeutics Inc
Investigators
Study Director: Michael Kauffman, MD, Ph.D Karyopharm Therapeutics Inc

Responsible Party: Karyopharm Therapeutics Inc
ClinicalTrials.gov Identifier: NCT02343042     History of Changes
Other Study ID Numbers: KCP-330-017
First Posted: January 21, 2015    Key Record Dates
Last Update Posted: April 9, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Keywords provided by Karyopharm Therapeutics Inc:
Selinexor
KCP-330
STOMP
Multiple Myeloma
Relapsed/Refractory
Dexamethasone
Pomalidomide
Bortezomib
Karyopharm
Lenalidomide
Daratumumab
Newly Diagnosed
Carfilzomib

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone acetate
Dexamethasone
Lenalidomide
Pomalidomide
Daratumumab
Thalidomide
Bortezomib
BB 1101
Antibodies, Monoclonal
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids